Oklo made real history in August. A nuclear chain reaction sustained itself inside Groves, the company's isotope test reactor in Lockhart, Texas, about eleven months after crews broke ground on an empty site. Days later, Oklo reported its first revenue in company history: roughly $1.2 million, mostly from services. For a company that has spent years trading on promises, that combination felt like a turning point.

It was a milestone. It was not a power business.

The gap between a reactor and a revenue stream

Oklo's actual product is electricity, sold from compact nuclear plants called Aurora powerhouses under long-term contracts. None of those plants exist yet. The company's valuation, which has attracted considerable investor attention, rests almost entirely on when the first one will start generating commercial power. And based on Oklo's own published schedule, that moment will not arrive before 2028.

The first Aurora powerhouse is planned for Idaho National Laboratory. Construction began with a groundbreaking on September 22, 2025. When Oklo named the project's lead constructor in July 2025, the company projected commercial operation in late 2027 or early 2028. By the most recent quarterly filing, that language had tightened into what management itself called "an ambitious target of deploying our first powerhouse in 2028." The earlier edge of the window is gone. The word "ambitious" is doing real work in that sentence.

This plant runs through a Department of Energy approval process rather than the slower Nuclear Regulatory Commission path, which is genuinely faster. But faster is not the same as simple. Oklo's filing describes five regulatory steps required before the plant can operate, and only two are finished: a Nuclear Safety Design Agreement, approved early in 2026, and a Preliminary Documented Safety Analysis, approved June 11. Three steps remain, each with its own review timeline.

The fuel problem compounds the schedule

Then there is fuel, which is its own constraint. The first reactor core depends on a Department of Energy award of five metric tons of high-assay low-enriched uranium, a specialized fuel type recovered from decades-old government reactor stockpiles. Oklo must fabricate that material into finished fuel rods at a new facility on the Idaho site. That fabrication plant does not yet exist either.

Longer term, the commercial fuel supply that would feed later Aurora powerhouses comes from Centrus Energy under a letter of intent. Deliveries from that agreement are not expected to begin until 2029.

So the picture is this: Oklo has a functioning test reactor and a small services revenue line, both of which are real achievements. But the five regulatory steps, the fuel fabrication buildout, and the construction timeline for Aurora-INL all point to 2028 at the earliest for any commercial power revenue, and that assumes nothing slips.

Why the distinction matters for anyone holding the stock

Growth stocks in capital-intensive industries are priced on when cash flow starts. Every year of delay is not just a scheduling inconvenience; it is a year of operating costs without offsetting revenue, and a year during which the discount on future earnings gets heavier. Oklo's August milestones were genuine and meaningful for the technology. But they did not move the commercial timeline forward. The distance between "we have a working test reactor" and "we are billing a utility for megawatts" is still measured in regulatory approvals, fuel supply chains, and construction schedules that management itself is calling ambitious.

The broader story here is about the pace at which nuclear ambition converts into nuclear infrastructure. Advanced reactor companies have been promising near-term deployment for years. Oklo is ahead of most of its competitors in concrete, operational terms. That is worth something. But the calendar has a way of reasserting itself, and 2028 is still two years away.